Sanofi SG&A Expenses 2010-2023 | SNY
Sanofi annual/quarterly sg&a expenses history and growth rate from 2010 to 2023. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Sanofi sg&a expenses for the quarter ending December 31, 2023 were $3.159B, a 5.92% increase year-over-year.
- Sanofi sg&a expenses for the twelve months ending December 31, 2023 were $11.572B, a 4.68% increase year-over-year.
- Sanofi annual sg&a expenses for 2023 were $11.572B, a 4.68% increase from 2022.
- Sanofi annual sg&a expenses for 2022 were $11.054B, a 2.21% decline from 2021.
- Sanofi annual sg&a expenses for 2021 were $11.305B, a 5.39% increase from 2020.
Sanofi Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$11,572 |
| 2022 |
$11,054 |
| 2021 |
$11,305 |
| 2020 |
$10,726 |
| 2019 |
$11,069 |
| 2018 |
$11,643 |
| 2017 |
$11,369 |
| 2016 |
$10,497 |
| 2015 |
$10,418 |
| 2014 |
$12,106 |
| 2013 |
$11,426 |
| 2012 |
$11,507 |
| 2011 |
$11,883 |
| 2010 |
$9,938 |
| 2009 |
$9,679 |
Sanofi Quarterly SG&A Expenses
(Millions of US $) |
| 2023-12-31 |
$3,159 |
| 2023-09-30 |
$2,807 |
| 2023-06-30 |
$2,808 |
| 2023-03-31 |
$2,798 |
| 2022-12-31 |
$2,982 |
| 2022-09-30 |
$2,663 |
| 2022-06-30 |
$2,739 |
| 2022-03-31 |
$2,670 |
| 2021-09-30 |
$2,673 |
| 2021-06-30 |
|
| 2021-03-31 |
$2,645 |
| 2020-09-30 |
$2,551 |
| 2020-03-31 |
$2,584 |
| 2019-09-30 |
$2,570 |
| 2019-03-31 |
$2,699 |
| 2018-03-31 |
$2,842 |
| 2017-12-31 |
$3,183 |
| 2017-09-30 |
$2,720 |
| 2017-06-30 |
$2,825 |
| 2017-03-31 |
$2,641 |
| 2016-12-31 |
$2,811 |
| 2016-09-30 |
$2,538 |
| 2016-06-30 |
$2,708 |
| 2016-03-31 |
$2,440 |
| 2015-09-30 |
$2,738 |
| 2015-06-30 |
$2,929 |
| 2014-06-30 |
$3,093 |
| 2013-06-30 |
$3,015 |
| 2012-06-30 |
$2,942 |
| 2012-03-31 |
$2,588 |
| 2011-12-31 |
$3,073 |
| 2011-09-30 |
$2,937 |
| 2011-06-30 |
$3,253 |
| 2011-03-31 |
$2,621 |
| 2010-12-31 |
$2,875 |
| 2010-09-30 |
$2,338 |
| 2010-06-30 |
$2,465 |
| 2010-03-31 |
$2,260 |
| 2009-12-31 |
$2,764 |
| 2009-09-30 |
$2,317 |
| 2009-06-30 |
$2,401 |
| 2009-03-31 |
$2,196 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$123.116B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
